Empirico
Empirico is seeking a chemist to support solid-phase oligonucleotide synthesis and analytics in the development of siRNA medicines. The role is based in Madison, WI and contributes to process development, characterization, and enabling scalable manufacturing for clinical programs.
Empirico is a biopharmaceutical company that combines human genetics-driven target discovery with siRNA drug discovery to develop novel siRNA medicines for common diseases with unmet medical need. Their proprietary technology platforms are designed to mimic naturally-occurring genetic variants that confer beneficial effects on health and disease. Empirico maintains a growing pipeline of differentiated clinical and preclinical programs and has partnered with major players such as GSK.
GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases
Oct 28, 2025
GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides
Oct 28, 2025
GSK forges pact with Empirico for respiratory siRNA in $745m deal
Oct 29, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Empirico.
Wilson Sonsini Advises Empirico on License Agreement with GSK
Oct 28, 2025